{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:39:01Z","timestamp":1793968741586,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3460-7","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T12:04:16Z","timestamp":1544616256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis"],"prefix":"10.1186","volume":"18","author":[{"given":"Hua-Zhen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Kui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stephen","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,12]]},"reference":[{"key":"3460_CR1","first-page":"675213","volume":"2013","author":"M Cogliati","year":"2013","unstructured":"Cogliati M. Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types. Scientifica (Cairo). 2013;2013:675213.","journal-title":"Scientifica (Cairo)"},{"key":"3460_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","volume":"17","author":"R Rajasingham","year":"2017","unstructured":"Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873\u201381.","journal-title":"Lancet Infect Dis"},{"key":"3460_CR3","doi-asserted-by":"publisher","first-page":"e56269","DOI":"10.1371\/journal.pone.0056269","volume":"8","author":"V Pyrgos","year":"2013","unstructured":"Pyrgos V, Seitz AE, Steiner CA, Prevots DR, Williamson PR. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One. 2013;8:e56269.","journal-title":"PLoS One"},{"key":"3460_CR4","first-page":"61","volume":"124","author":"PG Pappas","year":"2013","unstructured":"Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61\u201379.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"3460_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1086\/322597","volume":"33","author":"PG Pappas","year":"2001","unstructured":"Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33:690\u20139.","journal-title":"Clin Infect Dis"},{"key":"3460_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3109\/13693780903437876","volume":"48","author":"LP Zhu","year":"2010","unstructured":"Zhu LP, Wu JQ, Xu B, Ou XT, Zhang QQ, Weng XH. Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007. Med Mycol. 2010;48:570\u20139.","journal-title":"Med Mycol"},{"key":"3460_CR7","first-page":"419","volume":"61","author":"MH Nguyen","year":"2010","unstructured":"Nguyen MH, Husain S, Clancy CJ, et al. Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Inf Secur. 2010;61:419\u201326.","journal-title":"J Inf Secur"},{"key":"3460_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jmii.2011.12.005","volume":"45","author":"CH Liao","year":"2012","unstructured":"Liao CH, Chi CY, Wang YJ, et al. Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis. J Microbiol Immunol Infect. 2012;45:296\u2013304.","journal-title":"J Microbiol Immunol Infect"},{"key":"3460_CR9","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1086\/593194","volume":"47","author":"N Longley","year":"2008","unstructured":"Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47:1556\u201361.","journal-title":"Clin Infect Dis"},{"key":"3460_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/649861","volume":"50","author":"JC Nussbaum","year":"2010","unstructured":"Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2010;50:338\u201344.","journal-title":"Clin Infect Dis"},{"key":"3460_CR11","doi-asserted-by":"publisher","first-page":"e67311","DOI":"10.1371\/journal.pone.0067311","volume":"8","author":"C Rothe","year":"2013","unstructured":"Rothe C, Sloan DJ, Goodson P, et al. A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2013;8:e67311.","journal-title":"PLoS One"},{"key":"3460_CR12","doi-asserted-by":"publisher","first-page":"e110285","DOI":"10.1371\/journal.pone.0110285","volume":"9","author":"KM Gaskell","year":"2014","unstructured":"Gaskell KM, Rothe C, Gnanadurai R, et al. A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2014;9:e110285.","journal-title":"PLoS One"},{"key":"3460_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/13693780701851695","volume":"46","author":"E Milefchik","year":"2008","unstructured":"Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008;46:393\u20135.","journal-title":"Med Mycol"},{"key":"3460_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/cid\/cir745","volume":"54","author":"A Loyse","year":"2012","unstructured":"Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54:121\u20138.","journal-title":"Clin Infect Dis"},{"key":"3460_CR15","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1086\/599112","volume":"48","author":"PG Pappas","year":"2009","unstructured":"Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48:1775\u201383.","journal-title":"Clin Infect Dis"},{"key":"3460_CR16","doi-asserted-by":"publisher","first-page":"ofv157","DOI":"10.1093\/ofid\/ofv157","volume":"2","author":"MA Rolfes","year":"2015","unstructured":"Rolfes MA, Rhein J, Schutz C, et al. Cerebrospinal fluid culture positivity and clinical outcomes after amphotericin-based induction therapy for cryptococcal meningitis. Open Forum Infect Dis. 2015;2:ofv157.","journal-title":"Open Forum Infect Dis"},{"key":"3460_CR17","first-page":"293","volume":"86","author":"P Mootsikapun","year":"2003","unstructured":"Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg\/day versus itraconazole 600 mg\/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J Med Assoc Thail. 2003;86:293\u20138.","journal-title":"J Med Assoc Thail"},{"key":"3460_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","volume":"368","author":"JN Day","year":"2013","unstructured":"Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291\u2013302.","journal-title":"N Engl J Med"},{"key":"3460_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50:291\u2013322.","journal-title":"Clin Infect Dis"},{"key":"3460_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1086\/313757","volume":"30","author":"MS Saag","year":"2000","unstructured":"Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America Clin Infect Dis. 2000;30:710\u20138.","journal-title":"Infectious Diseases Society of America Clin Infect Dis"},{"key":"3460_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","volume":"47","author":"BH Segal","year":"2008","unstructured":"Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674\u201383.","journal-title":"Clin Infect Dis"},{"key":"3460_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/jac\/dki288","volume":"56","author":"P Pitisuttithum","year":"2005","unstructured":"Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56:745\u201355.","journal-title":"J Antimicrob Chemother"},{"key":"3460_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2008.04.019","volume":"20","author":"HS Rehan","year":"2009","unstructured":"Rehan HS, Chopra D, Kakkar AK. Physician's guide to pharmacovigilance: terminology and causality assessment. Eur J Intern Med. 2009;20:3\u20138.","journal-title":"Eur J Intern Med"},{"key":"3460_CR24","first-page":"873","volume":"23","author":"P Pappas","year":"1996","unstructured":"Pappas P, Hamill R, Kauffman C, Bradsher R, McKinsey D, We GC. Treatment of cryptococcal meningitis in non-HIV infected patients \u2013 a randomized comparative trial. Clin Infect Dis. 1996;23:873.","journal-title":"Clin Infect Dis"},{"key":"3460_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJM198708063170602","volume":"317","author":"WE Dismukes","year":"1987","unstructured":"Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987;317:334\u201341.","journal-title":"N Engl J Med"},{"key":"3460_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1056\/NEJM197907193010303","volume":"301","author":"JE Bennett","year":"1979","unstructured":"Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med. 1979;301:126\u201331.","journal-title":"N Engl J Med"},{"key":"3460_CR27","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1086\/516353","volume":"26","author":"TJ Walsh","year":"1998","unstructured":"Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383\u201396.","journal-title":"Clin Infect Dis"},{"key":"3460_CR28","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1086\/374557","volume":"36","author":"JR Perfect","year":"2003","unstructured":"Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122\u201331.","journal-title":"Clin Infect Dis"},{"key":"3460_CR29","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1086\/425121","volume":"39","author":"MG Netea","year":"2004","unstructured":"Netea MG, Brouwer AE, Hoogendoorn EH, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin Infect Dis. 2004;39:e83\u20137.","journal-title":"Clin Infect Dis"},{"key":"3460_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3109\/13693780903325282","volume":"48","author":"NE Nierenberg","year":"2010","unstructured":"Nierenberg NE, Thompson GR, Lewis JS, Hogan BK, Patterson TF. Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. Med Mycol. 2010;48:532\u20136.","journal-title":"Med Mycol"},{"key":"3460_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diagmicrobio.2012.08.009","volume":"74","author":"MN Gamaletsou","year":"2012","unstructured":"Gamaletsou MN, Sipsas NV, Kontoyiannis DP, et al. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-gamma. Diagn Microbiol Infect Dis. 2012;74:409\u201311.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3460_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1128\/AAC.36.3.690","volume":"36","author":"AJ Berry","year":"1992","unstructured":"Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 1992;36:690\u20132.","journal-title":"Antimicrob Agents Chemother"},{"key":"3460_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7326\/0003-4819-80-2-176","volume":"80","author":"RD Diamond","year":"1974","unstructured":"Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974;80:176\u201381.","journal-title":"Ann Intern Med"},{"key":"3460_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/infdis\/170.1.238","volume":"170","author":"RH Haubrich","year":"1994","unstructured":"Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. J Infect Dis. 1994;170:238\u201342.","journal-title":"J Infect Dis"},{"key":"3460_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/172.2.599","volume":"172","author":"EJ Anaissie","year":"1995","unstructured":"Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis. 1995;172:599\u2013602.","journal-title":"J Infect Dis"},{"key":"3460_CR36","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000239592","volume":"43","author":"DA Stevens","year":"1997","unstructured":"Stevens DA, Diaz M, Negroni R, et al. Safety evaluation of chronic fluconazole therapy. Fluconazole pan-American study group. Chemotherapy. 1997;43:371\u20137.","journal-title":"Chemotherapy"},{"key":"3460_CR37","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/clinids\/22.5.838","volume":"22","author":"F Menichetti","year":"1996","unstructured":"Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996;22:838\u201340.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3460-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:09:20Z","timestamp":1576109360000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3460-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3460"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3460-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"16 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the local medical Ethics Committee of Huashan Hospital, Fudan University, Shanghai, China. As this is a retrospective study, data was obtained through medical records and analyzed anonymously, and therefore informed consent of the participants was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TSH reports an investigator award and honoraria from Gilead Sciences, advisory board fees from Viamet, gift of tests for research from Immuno-Mycologics, and honoraria from Pfizer. All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"643"}}